Karyopharm Therapeutics (KPTI) Misses Q1 EPS by 124c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($1.24). Revenue for the quarter came in at $35.07 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• UAE Says Situation Currently Safe After Potential Threat Alert
• Benchmark Reiterates Buy Rating on IMAX Corporation (IMAX), Highlights 'The Odyssey' Potential
• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance